MedTrace Logo

A Study of Supaglutide in Chinese Type 2 Diabetes Patients

NCT04314622 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-09-17

No results posted yet for this study

Summary

A study on the safety, efficacy, pharmacokinetics and pharmacodynamics of Supaglutide dosing weekly and bi-weekly in patients with type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Supaglutide

Administered SC

DRUG

Placebo

Administered SC

Sponsors & Collaborators

  • Shanghai 6th People's Hospital

    collaborator OTHER

  • Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

    lead OTHER

Principal Investigators

  • Weiping Jia, Doctor · Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital

  • Yuqian Bao, Doctor · Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-14
Primary Completion
2020-10-25
Completion
2021-03-16

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04314622 on ClinicalTrials.gov